CTSO
CytoSorbentsCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
Current thesis
The best bull argument is that CTSO still has live regulatory optionality around DrugSorb-related FDA discussions while Q1 showed direct-sales growth outside Germany, lower operating loss, and early benefits from prior cost cuts [#SEC-8K-2026-05-13] [#8-K-2026-06-25].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern risk remains explicit in the 10-Q, with management noting additional capital may be required if needed funding is not available [#10-Q-2026-05-13].
Momentum
79
Value
37
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.30 · Bull $0.70 · Bear $0.15
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $0.75
Why
Momentum79 · Δ7d -
Value37 · Δ7d -0.0
Sentiment52 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
52
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 78.8 / Value 36.5 / Sentiment 52.3
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$22.71M
Beta
1.39
Shares Out
62.84M
P/E (TTM) · Derived
-2.7
P/S (TTM)
1.22
P/FCF (TTM) · Derived
-2.24
Rev YoY
+1.6%
EPS YoY
+236.6%
Gross Margin
+71.0%
Op Margin
-41.9%
Net Debt
$23.13M
Current Ratio
1.09
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology